Compare IDEXX Laboratories, Inc. (IDXX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs J M Smucker Co — how do they compare? IDEXX Laboratories, Inc. trades at $551.53 (market cap $44.48B), while J M Smucker Co trades at $114.42 (market cap $11.97B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.7× J M Smucker Co's market cap, and J M Smucker Co pays a 3.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | SJM | |
|---|---|---|
Market Cap | $44.48B | $11.97B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $117.05 |
52-Week Low | $520.87 | $89.53 |
Enterprise Value | $45.38B | $19.00B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
J.M. Smucker (SJM) trades at $112.66, up 0.58% today, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 results are pending. The company maintains a solid dividend, recently increased to $1.12 per share, and benefits from growth in Uncrustables and coffee segments. However, negative net income margin and ROE highlight profitability challenges amid revenue growth to $8.73 billion in 2025.
SJM presents a mixed outlook: valuation metrics like P/E of 22.05 and P/S of 1.32 suggest reasonable pricing, but persistent net losses and high debt pose risks. Analyst price targets average $123.18, implying upside, yet investors must weigh competitive pressures and volatile cash flows against dividend stability and brand strength in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
